GSK's Blenrep Approved in China for Relapsed/Refractory Multiple Myeloma
Summary
GSK announced that its oncology drug, Blenrep, has received approval from China's NMPA for treating relapsed or refractory multiple myeloma, expanding its global market presence.
Key Events
-
China NMPA Approval
Blenrep (belantamab mafodotin) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adults with 2L+ relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone (BVd).
-
Strong Clinical Data
The approval is supported by pivotal DREAMM-7 phase III trial data, which showed a 42% reduction in the risk of death and nearly tripled median progression-free survival compared to a daratumumab-based triplet.
-
Significant Market Expansion
This approval opens a substantial new market in China, where the incidence of multiple myeloma has doubled to approximately 30,000 new cases annually.
-
Differentiated Therapy
Blenrep is highlighted as the only anti-BCMA approved in 2L+ multiple myeloma in China and the only fully outpatient anti-BCMA therapy, minimizing patient and healthcare burden.
Analysis
This approval in China for Blenrep (belantamab mafodotin) is a significant positive development for GSK, opening a substantial new market for a key oncology product. Multiple myeloma incidence in China is growing, and Blenrep offers a differentiated, outpatient anti-BCMA therapy with strong clinical data, including a 42% reduction in the risk of death and nearly tripled progression-free survival in the DREAMM-7 trial. This expands GSK's footprint in a critical therapeutic area and geographic region.
At the time of this filing, GSK was trading at $57.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $115.7B. The 52-week trading range was $35.08 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.